+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroparesis Drugs Market - Global Forecast 2026-2032- Product Image
Gastroparesis Drugs Market - Global Forecast 2026-2032- Product Image
New

Gastroparesis Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5924669
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gastroparesis drugs market is evolving rapidly, driven by clinical innovation, new delivery mechanisms, and shifting regulatory expectations. Senior decision-makers need a clear view of the commercial and operational dynamics influencing this essential area of gastrointestinal pharmacotherapy.

Market Snapshot

The Gastroparesis Drugs Market grew from USD 4.87 billion in 2025 to USD 5.24 billion in 2026. It is expected to continue growing at a CAGR of 7.27%, reaching USD 7.97 billion by 2032. Market expansion is supported by therapeutic innovation, an expanded spectrum of product types, intensified manufacturer competition, and global regulatory developments impacting procurement strategies.

Scope & Segmentation

This report delivers comprehensive intelligence for the gastroparesis drugs market, focusing exclusively on prescription pharmacotherapies for motility and symptomatic management. The analysis intentionally excludes surgical and device-based interventions.

  • Product Types: Branded products, Generics
  • Pharmacologic Classes: Dopamine Antagonists (e.g., Cisapride, Domperidone, Metoclopramide), Motilin Receptor Agonists (e.g., Azithromycin, Erythromycin), Serotonin Receptor Agonists (e.g., Granisetron, Ondansetron)
  • Administration Routes: Injectable, Oral, Transdermal
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • End Users: Clinics, Home Care, Hospitals
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific

Key coverage extends across regulatory frameworks, payer dynamics, supply chain strategies, and technology adoption for prokinetic and symptomatic agents.

Key Takeaways

  • Clinical decision-making in gastroparesis drugs is shaped by the interplay of efficacy, safety, and administration convenience. Product differentiation is increasingly based on tolerability, formulation, and evidence generation.
  • Therapeutic innovation emphasizes the development of new delivery systems, such as novel oral, transdermal, and injectable formulations. These enable tailored patient management, particularly for complex or comorbid populations.
  • Manufacturers are adapting their commercial strategies to address payer demands for comparative-effectiveness data and to strengthen post-marketing surveillance partnerships, which are now vital for long-term adoption.
  • Segmented market approaches are essential. Branded drugs compete on clinical value, while generics rely on pricing and availability. Each distribution channel and care setting, from hospitals to home care, requires distinctive commercialization tactics.
  • Regional variations—such as regulatory stringency, supply chain capacity, and healthcare infrastructure—require customized launch strategies and local partnerships for successful market entry and growth.
  • Operational resilience is a priority. Companies are reinforcing their portfolios to support multi-channel distribution and investing in digital health initiatives for optimized patient and provider engagement.

Tariff Impact

Current and projected United States tariff adjustments influence supply chain costs and procurement behaviors throughout the gastroparesis drugs value chain. Manufacturers may revise sourcing models or pursue onshoring to manage cost volatility, while hospitals emphasize therapeutically equivalent generics to counter input price increases. Smaller providers might experience deferred access to newer therapies if manufacturers shift allocation strategies. Companies are responding by strengthening supplier relationships, diversifying manufacturing bases, and prioritizing transparent value communication to payers and providers.

Methodology & Data Sources

This analysis combines structured interviews with key clinical and supply chain stakeholders, a systematic review of peer-reviewed literature, regulatory documents, and commercial data on pharmaceutical distribution. Operational scenario analysis evaluates potential impacts of trade disruptions and supply chain shifts. Robust quality controls include expert peer review and validated source triangulation to ensure actionable insights.

Why This Report Matters

  • Enables leadership teams to benchmark emerging therapeutic and operational strategies in gastroparesis pharmacotherapy against evolving global market forces.
  • Supports evidence-driven investment, launch, and channel management decisions by highlighting clinically relevant segmentation and regional nuances.
  • Equips commercial and clinical executives to proactively manage risk, strengthen value communication, and optimize patient access amidst ongoing regulatory and supply chain shifts.

Conclusion

Sustained commercial success in gastroparesis drugs depends on clinical differentiation, agile supply chain management, and regionally tailored go-to-market strategies. Organizations capable of integrating these elements will be positioned for durable growth in a changing therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gastroparesis Drugs Market, by Product Type
8.1. Branded
8.2. Generics
9. Gastroparesis Drugs Market, by Drug Class
9.1. Dopamine Antagonists
9.1.1. Cisapride
9.1.2. Domperidone
9.1.3. Metoclopramide
9.2. Motilin Receptor Agonists
9.2.1. Azithromycin
9.2.2. Erythromycin
9.3. Serotonin Receptor Agonists
9.3.1. Granisetron
9.3.2. Ondansetron
10. Gastroparesis Drugs Market, by Route Of Administration
10.1. Injectable
10.2. Oral
10.3. Transdermal
11. Gastroparesis Drugs Market, by End User
11.1. Clinics
11.2. Home Care Settings
11.3. Hospitals
12. Gastroparesis Drugs Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Gastroparesis Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Gastroparesis Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Gastroparesis Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Gastroparesis Drugs Market
17. China Gastroparesis Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. AbbVie Inc.
18.7. Amneal Pharmaceuticals, Inc.
18.8. ANI Pharmaceuticals, Inc.
18.9. AstraZeneca PLC
18.10. Atlantic Healthcare PLC
18.11. Bausch Health Companies Inc.
18.12. Bristol-Myers Squibb Company
18.13. Cadila Pharmaceuticals Limited
18.14. Cairn Diagnostics
18.15. Evoke Pharma, Inc.
18.16. GlaxoSmithKline PLC
18.17. Johnson & Johnson Services, Inc.
18.18. Kyowa Kirin International plc
18.19. Lupin Limited
18.20. Medtronic PLC
18.21. Neurogastrx, Inc.
18.22. Novartis AG
18.23. Pfizer, Inc.
18.24. Processa Pharmaceuticals, Inc.
18.25. Sanofi S.A.
18.26. Takeda Pharmaceutical Company Limited
18.27. Theravance Biopharma
18.28. Vanda Pharmaceuticals Inc.
18.29. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 112. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 130. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 132. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 133. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 134. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 149. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 150. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 151. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 152. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 153. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GCC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 158. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 160. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 161. GCC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 162. GCC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. GCC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 176. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 177. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 178. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 179. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 180. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. G7 GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. G7 GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 185. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 186. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 187. G7 GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 188. G7 GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 189. G7 GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. G7 GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. NATO GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. NATO GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 194. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 195. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 196. NATO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 197. NATO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 198. NATO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. NATO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. CHINA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 213. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 214. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 215. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 216. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 217. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Gastroparesis Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Atlantic Healthcare PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Cairn Diagnostics
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Medtronic PLC
  • Neurogastrx, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Processa Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.97 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Gastroparesis Drugs - Global Strategic Business Report - Product Image

Gastroparesis Drugs - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Gastroparesis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Gastroparesis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2025-2033 - Product Image

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2025-2033

  • Report
  • 138 Pages
  • Global
From
Diabetic Gastroparesis Drug Pipeline Analysis Report 2025 - Product Image

Diabetic Gastroparesis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Gastroparesis Drugs Market Report 2025 - Product Image

Gastroparesis Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Gastroparesis Drug Market

Gastroparesis Drug is a type of drug used to treat gastroparesis, a condition in which the stomach muscles are weakened and unable to properly move food through the digestive system. These drugs are used to reduce symptoms such as nausea, vomiting, bloating, and abdominal pain. Commonly prescribed drugs for gastroparesis include metoclopramide, domperidone, and erythromycin. Other drugs, such as prokinetics, may also be used to help improve gastric emptying. Gastroparesis Drug is a part of the larger Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal conditions. These drugs are used to reduce symptoms, improve digestion, and prevent further complications. Commonly prescribed drugs in this market include antacids, proton pump inhibitors, and laxatives. Some companies in the Gastroparesis Drug market include Novartis, GlaxoSmithKline, Pfizer, and Takeda. Other companies, such as Allergan, Merck, and AstraZeneca, also produce drugs for the treatment of gastroparesis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.